Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company's cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up for a FREE account ($89 per month value), and get immediate access. Free offer expires March 15, 2019.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2